Business Context and Reporting Period
Company: Akebia Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 16, 2015
Event: Entry into a Material Definitive Agreement regarding a public offering of common stock.
Key Financial Metrics
This filing details a capital raise event rather than operational financial results. Specific metrics include:
- Shares Offered: 7,272,727 shares of Common Stock.
- Offering Price: $8.25 per share.
- Over-Allotment Option: Underwriters granted an option to purchase an additional 1,090,909 shares.
- Expected Closing Date: April 22, 2015.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the execution of an underwriting agreement with UBS Securities LLC and Morgan Stanley & Co. LLC. This agreement facilitates the public offering of the Company's common stock pursuant to a registration statement on Form S-3 (File No. 333-203206).
Guidance, Outlook, and Risks
Management Commentary: The Company expects the Offering to close on April 22, 2015, subject to customary closing conditions.
Risks and Contingencies: The completion of the offering is contingent upon the satisfaction of customary closing conditions. The description of the Underwriting Agreement is qualified in its entirety by reference to the full agreement filed as Exhibit 1.1.
Investor Verification Checklist
- Verify the final closing date of the offering (expected April 22, 2015).
- Confirm whether the underwriters exercised the option to purchase the additional 1,090,909 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific underwriting discounts and commissions.
- Check subsequent filings for the actual net proceeds received by the Company.